What is ChromaDex Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ChromaDex's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ChromaDex's Operating Income for the
three
months ended in Dec. 2023 was $ -0.17 Mil. ChromaDex's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate ChromaDex's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ChromaDex Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ChromaDex (NAS:CDXC) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ChromaDex's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-0.17 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $2.58 Mil.
ChromaDex's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate ChromaDex's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. ChromaDex Corp has enough cash to cover all of its debt. Its financial situation is stable.
ChromaDex (ChromaDex) Business Description
Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.
Executives
| Brianna Gerber |
officer: SVP Finance / Interim CFO |
C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782 |
| Champion River Ventures Ltd |
10 percent owner |
C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000 |
| Jaksch Frank L Jr |
director, 10 percent owner, officer: Chief Executive Officer |
10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618 |
| Robert N Fried |
director |
100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210 |
| Steven D Rubin |
director |
OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137 |
| Li Ka Shing |
10 percent owner |
79 DEEP WATER BAY ROAD, HONG KONG F4 00000 |
| Chau Hoi Shuen Solina Holly |
10 percent owner |
SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077 |
| Hamed Shahbazi |
director |
C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782 |
| Ann Cohen |
director |
C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024 |
| Kristin Patrick |
director |
3329 CAY DRIVE, SHERMAN OAKS CA 91423 |
| Ng Wang Yu Gary |
director |
ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 - |
| Caroline S Levy |
director |
2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431 |
| Stephen A Block |
director |
INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019 |
| Lisa Hatton Harrington |
officer: General Counsel |
53 SEA TERRACE, NEWPORT COAST CA 92657 |
| Kevin M Farr |
officer: Chief Financial Officer |
MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245 |
ChromaDex (ChromaDex) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDXC has been successfully added to your 